In a move that has left both the biotech and crypto communities scratching their heads, 180 Life Sciences has announced a plan to pivot to Ethereum with a $425 million private placement, because why not? 🤷♂️
Hold My Beer: Biotech Company Rebrands as ETHzilla, Now Officially a Crypto Dinosaur
180 Life Sciences Corp. (Nasdaq: ATNF) has decided that curing diseases was too mainstream. Instead, they’re launching ETHzilla, a creature that’s half corporate strategy, half cryptocurrency chaos. 🚀
The PIPE (because acronyms make everything sound official) priced at $2.65 per share includes over 60 investors, including names like Electric Capital and Polychain Capital. Fun fact: None of them are named Dr. Evil, but we’re not convinced. 🕵️♂️
The plan? Buy ETH and hope it doesn’t crash harder than a poorly coded smart contract. Electric Capital will manage the treasury, promising “yield-generation” via staking, lending, and “private agreements” (which we’re 80% sure is just a fancy term for handshake deals at crypto conferences). 💸
By adopting ETH as its principal treasury asset, 180 Life Sciences joins the growing club of companies asking the universe: “How much weirder can we make this?” Spoiler: The universe is still answering. 🌌
For more groundbreaking news, like “Water is Wetcoin” or “Moon Lambo Update: Still Not Here,” stay tuned. 🌕
Read More
- Gold Rate Forecast
- Brent Oil Forecast
- Silver Rate Forecast
- HBAR: $32 Million Hangs in the Balance! 😲
- UK Adopts a Quixotic Crypto Quandary with BoE’s Capri-cious Stablecoin Strategy
- Winners & Whiners: PUMP Tokens Soar After Pump.Fun Grabs Padre, But Not Everyone’s Happy!
- Oh My Goodness! Will PENGU Balloons to a Whopping 38%? Find Out Now! 🐧💥
- CNY JPY PREDICTION
- Crypto Market Madness 🚀
- When Ethereum Coughs, Traders Rush for the Tissues 🤧💰
2025-07-31 10:18